The combination of GOLPH2 and AMACR showed expression of either marker in 99.2% of cancer cases, which advocates a combined use of AMACR and GOLPH2 as positive confirmative markers of prostate cancer. The gene discussed is GOLM1; the disease is prostate carcinoma.